Brenntag and dsm-firmenich expand biopharma vitamin partnership

pharmafile | October 4, 2026 | News story | |  Biopharmaceuticals, Pharmacy, cell culture, manufacturing 

Brenntag Pharma and dsm-firmenich have entered a long-term global distribution partnership covering GMP-grade vitamins for biopharmaceutical manufacturing.

Under the agreement, Brenntag will have exclusive distribution rights across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific for dsm-firmenich’s Biond portfolio of high-purity vitamins.

The products will be marketed under the new BYPHAR powered by Biond co-brand, with eight products available in multiple pack sizes. The vitamins are intended for use in cell culture and feed media and upstream bioprocessing for the manufacture of biologics, vaccines and cell therapies.

Advertisement

Brenntag said the partnership expands its biopharma ingredients portfolio and will provide customers with access to GMP-grade vitamins, alongside technical support and global distribution.

The agreement builds on a partnership between the two companies spanning more than 30 years.

Related Content

BioDuro establishes joint manufacturing venture with Cenra

BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with …

CARBOGEN AMCIS manufacturing license advances services in China

Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

Meribel Pharma Solutions launches to take pharma services to new heights

Meribel Pharma Solutions, a new mid-sized contract development and manufacturing organisation (CDMO), has officially launched …

The Gateway to Local Adoption Series

Latest content